Jun 18, 2020
Innovent Announces First Patient Dosed in A Phase 1b/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China
Jun 13, 2020
Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections
Nov 17, 2019
Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
Sep 20, 2019
FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes
Sep 20, 2019
FDA approves first oral GLP-1 treatment for type 2 diabetes
Jun 18, 2019
Oramed Provides Clinical Update with Meaningful Data Expected by Year-End
Jun 11, 2019
Oral Semaglutide Reduces Occurrence of Major Cardiac Events in People with Type 2 Diabetes With High Cardiovascular Risk
Jun 08, 2019
Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79 Scientific Sessions®
Jan 22, 2019
Oramed Initiates Phase I Oral GLP-1 Study Under IND
Nov 05, 2018
Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes
Oct 04, 2018
Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes
Sep 17, 2018
Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule
Aug 09, 2018
I-Mab's Announces China Clinical Trial Approval of Long-acting hGLP-1 to Treat Type 2 Diabetes
Jul 24, 2018
Oramed Granted Japanese Patent for GLP-1 Analog Capsule
Jun 24, 2018
Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW
Jun 23, 2018
Investigational Doses of Lilly's Once-Weekly Trulicity® (dulaglutide) Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes
Jun 23, 2018
Real-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients
Apr 23, 2018
Peptron Expands Exclusive License with NIH to Support Developing SR-exenatide to Treat Neurodegenerative Diseases
Jan 04, 2018
Spitfire Pharma's SP-1373 outscored semaglutide and elafibranor in a biopsy-proven translational mouse model of non-alcoholic steatohepatitis (NASH)
Jun 27, 2017
Oramed Granted Japanese Patent for Combination Insulin and GLP-1 Analog Capsule